Myeloid-derived suppressor cells and radiotherapy

C Jiménez-Cortegana, C Galassi, V Klapp… - Cancer Immunology …, 2022 - AACR
Cancer Immunology Research, 2022AACR
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of pathologically
activated, mostly immature, myeloid cells that exert robust immunosuppressive functions.
MDSCs expand during oncogenesis and have been linked to accelerated disease
progression and resistance to treatment in both preclinical tumor models and patients with
cancer. Thus, MDSCs stand out as promising targets for the development of novel
immunotherapeutic regimens with superior efficacy. Here, we summarize accumulating …
Abstract
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of pathologically activated, mostly immature, myeloid cells that exert robust immunosuppressive functions. MDSCs expand during oncogenesis and have been linked to accelerated disease progression and resistance to treatment in both preclinical tumor models and patients with cancer. Thus, MDSCs stand out as promising targets for the development of novel immunotherapeutic regimens with superior efficacy. Here, we summarize accumulating preclinical and clinical evidence indicating that MDSCs also hamper the efficacy of radiotherapy (RT), as we critically discuss the potential of MDSC-targeting strategies as tools to achieve superior immunotherapeutic tumor control by RT in the clinic.
AACR